Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: A controlled randomized study (CALMAG study) assessing efficacy and tolerability

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3707-3717

  De Francisco, Angel L M ^a   Leidig, Michael ^b   Covic, Adrian C ^c   Ketteler, Markus ^d   Benedyk Lorens, Ewa ^e   Mircescu, Gabriel M ^f   Scholz, Caecilia ^g   Ponce, Pedro ^h   Passlick Deetjen, Jutta ^g  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b Kuratorium für Heimdialyse ^*  (Germany)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d KLINIKUM COBURG   (Germany)

^e Fresenius Nephro Care   (Poland)

^f Clin Nephrol Hosp Dr Carol Davila   (Romania)

^g FRESENIUS MEDICAL CARE   (Germany)

^h Almada NMC Centro Médico Nacional   (Portugal)

Author keywords

Calcium acetate; Haemodialysis; Magnesium carbonate; Phosphate binder; Safety parameters

Indexed keywords

CALCIUM ACETATE; CALCIUM ION; MAGNESIUM; MAGNESIUM CARBONATE; OSVAREN; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; ALKALINE PHOSPHATASE; CALCIUM DERIVATIVE; PARATHYROID HORMONE; POLYAMINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE SPASM; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ACETATES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CALCIUM COMPOUNDS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MAGNESIUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS;

EID: 78650315397     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq292     Document Type: Article

References (50)

1. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
2. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523
3. Lezaic V, Tirmenstajn-Jankovic B, Bukvic D et al. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol 2009; 71: 21-29
4. Wald R, Sarnak MJ, Tighiouart H et al. Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-540
5. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
6. Plantinga LC, Fink NE, Melamed ML et al. Serum phosphate levels and risk of infection in incident dialysis patients. Clin J Am Soc Nephrol 2008; 3: 1398-1406
7. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130
8. Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 2006; 1: 704-709
9. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914-1926 (Pubitemid 38591044)
10. QunibiW, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965 (Pubitemid 351697566)
11. Ring T, Nielsen C, Andersen SP et al. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study. Nephrol Dial Transplant 1993; 8: 341-346 (Pubitemid 23129902)
12. Schaefer K, Scheer J, Asmus G et al. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol Dial Transplant 1991; 6: 170-175
13. Delmez JA, Tindira CA, Windus DWet al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3: 96-102
14. Delmez JA, Kelber J, Norword KY et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 1996; 49: 163-167 (Pubitemid 26024233)
15. Spiegel DM, Farmer B, Smits G et al. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: A pilot study. J Ren Nutr 2007; 17: 416-422 (Pubitemid 350001351)
16. Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial 2007; 20: 333-336
17. Spiegel DM, Farmer B. Long-Term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009; 13: 453-459
18. Tzanakis IP, Papadaki AN, Wei M et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008; 40: 193-201
19. Deuber HJ. Long-Term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. Nieren-und Hochdruckkrankheiten 2004; 33: 403-408
20. Tzanakis I, Pras A, Kounali D et al. Mitral annular calcifications in haemodialysis patients: A possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-2037 (Pubitemid 27379500)
21. Ishimura E, Okuno S, Kitatani Ket al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007; 68: 222-227 (Pubitemid 47527442)
22. Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244
23. Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009; 22: 37-44
24. Kanbay M, Goldsmith D, Uyar ME et al. Magnesium in chronic kidney disease: Challenges and opportunities. Blood Purif 2009; 1-13. doi:10.1159/000XXXXXX
25. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-394 (Pubitemid 17147886)
26. Turgut F, Kanbay M, Metin MR et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008; 40: 1075-1082
27. Eypasch E, Williams JI, Wood-Dauphinee S et al. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg 1995; 82: 216-222
28. Schmidt-Gayk H. Measurement of calcium, phosphate and magnesium. In: MJ Seibel, SP Robins, JP Bilezikian (eds). Dynamics of Bone and Cartilage Metabolism. Burlington, San Diego, London: Academic Press, 2006; 487-505
29. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallelgroup randomised trials. Lancet 2001; 357: 1191-1194 (Pubitemid 32378696)
30. K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201
31. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252 (Pubitemid 34754068)
32. Evenepoel P, Selgas R, Caputo F et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009; 24: 278-285
33. Tonelli M,Wiebe N, Culleton B et al. Systematic reviewof the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866 (Pubitemid 350093462)
34. Navaneethan SD, Palmer SC, Craig JC et al. Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54: 619-637
35. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824 (Pubitemid 43169927)
36. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835
37. Asmus HG, Braun J, Krause R et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-1661 (Pubitemid 41418591)
38. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261 (Pubitemid 350059663)
39. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: C8-19
40. Shaheen FA, Akeel NM, Badawi LS et al. Efficacy and safety of sevelamer. Comparisonwith calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25: 785-791 (Pubitemid 38877924)
41. Oe PL, Lips P, van der MJ et al. Long-Term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 1987; 28: 180-185 (Pubitemid 17154324)
42. McIntyre CW, Pai P, Warwick G et al. Iron-magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 401-409
43. Moriniere P, Vinatier I, Westeel PF et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988; 3: 651-656 (Pubitemid 19000996)
44. Guillot AP, Hood VL, Runge CF et al. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982; 30: 114-117 (Pubitemid 12146990)
45. Saha H, Harmoinen A, Pietila K et al. Measurement of serum ionized versus total levels of magnesium and calcium in hemodialysis patients. Clin Nephrol 1996; 46: 326-331 (Pubitemid 26390756)
46. Navarro-Gonzalez JF. Magnesium in dialysis patients: Serum levels and clinical implications. Clin Nephrol 1998; 49: 373-378 (Pubitemid 28271469)
47. Kelber J, Slatopolsky E, Delmez JA. Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis. Am J Kidney Dis 1994; 24: 453-460 (Pubitemid 24277942)
48. Nilsson P, Johansson SG, Danielson BG. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nephron 1984; 37: 25-29 (Pubitemid 14152934)
49. Boskey AL, Posner AS. Effect of magnesium on lipid-induced calcification: An in vitro model for bone mineralization. Calcif Tissue Int 1980; 32: 139-143 (Pubitemid 11234463)
50. van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. Lab Anim 1998; 32: 483-491 (Pubitemid 28482484)